Both in Biotechnology
ADMA Biologics vs Replimune Group
Over the past year ADMA returned −27.7% and REPL returned +121.9%; their daily moves had a correlation of -0.08.
ADMA −27.7% REPL +121.9%Growth of $1, one year, split-adjusted
| Metric | ADMA | REPL |
|---|---|---|
| Price | $11.11 | $20.65 |
| Market cap | $2.49B | $1.96B |
| Today | +0.45% | +5.95% |
| 1 month | +9.9% | +57.0% |
| 6 months | +8.4% | +619.5% |
| Year to date | −39.1% | +112.4% |
| 1 year | −28.2% | — |
| Revenue growth (YoY) | +2.0% | — |
| Gross margin | 69.4% | — |
| Net margin | 30.4% | — |
| P/E (TTM) | 14.7× | — |
| Price / sales | 4.9× | — |
| Net cash | -$60.6M | $183.7M |
| Dividend yield | — | — |
| Volatility (60d) | 38.5% | 77.7% |
| Short % of float | 9.1% | 29.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).